title: Improving the use of ranking in virtual screening against HIV-1 integrase with triangular numbers and including ligand profiling with antitargets.
abstract: A delicate balance exists between a drug molecule's toxicity and its activity. Indeed, efficacy, toxicity, and side effect problems are a common cause for the termination of drug candidate compounds and development projects. To address this, an antitarget interaction profile is built and combined with virtual screening and cross docking for new inhibitors of HIV-1 integrase, in order to consider possible off-target interactions as early as possible in a drug or hit discovery program. New ranking techniques using triangular numbers improve ranking information on the compounds and recovery of known inhibitors into the top compounds using different docking programs. This improved ranking arises from using consensus of ranks between docking programs and ligand efficiencies to derive a new rank, instead of using absolute score values, or average of ranks. The triangular number rerank also allowed the objective combination of results from several protein targets or screen conditions and several programs. Triangular number reranking conserves more information than other reranking methods such as average of scores or averages of ranks. In addition, the use of triangular numbers for reranking makes possible the use of thresholds with a justified leeway based on the number of available known inhibitors, so that the majority of the compounds above the threshold in ranks compare to the compounds that have known experimentally determined biological activity. The battery of anti- or off-targets can be tailored to specific molecular or drug design challenges. In silico filters can thus be deployed in successive stages, for prefiltering, activity profiling, and for further analysis and triaging of libraries of compounds.
authors.affiliation: Institute of Chemistry, University of Tartu , Ravila14a, Tartu 50411, Estonia.
authors.forename: Alfonso T
authors.initials: AT
authors.lastname: García-Sosa
authors.forename: Uko
authors.initials: U
authors.lastname: Maran
mesh_terms: D004353:Drug Evaluation, Preclinical / Q000379:methods*; D019427:HIV Integrase / Q000737:chemistry / Q000378:metabolism*; D019428:HIV Integrase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D008024:Ligands; D062105:Molecular Docking Simulation; D011487:Protein Conformation; D014584:User-Computer Interface
chemical_list: D019428:HIV Integrase Inhibitors; D008024:Ligands; D019427:HIV Integrase; C514801:p31 integrase protein, Human immunodeficiency virus 1